Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709027 | 0.88 | PTGS2 (0.64) | PTGS2 | |
| SCHEMBL7254206 | 0.88 | PTGS2 (0.64) | PTGS2 | |
| SCHEMBL5708983 | 0.86 | PTGS2 (0.67) | PTGS2 | |
| SCHEMBL7254559 | 0.85 | PTGS2 (0.71) | PTGS2 | |
| SCHEMBL5709000 | 0.85 | PTGS2 (0.59) | PTGS2 | |
| SCHEMBL7259692 | 0.84 | PTGS2 (0.67) | PTGS2 | |
| SCHEMBL7254993 | 0.84 | PTGS2 (0.69) | PTGS2 | |
| SCHEMBL7259192 | 0.83 | PTGS2 (0.53) | PTGS2 | |
| SCHEMBL7023771 | 0.83 | PTGS2 (0.61) | PTGS2 | |
| SCHEMBL5709021 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299372-A1 | PYRONES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 2003-04-09 | — | — | EP | claimed |
| US-6465509-B2 | FOR THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISEASE SUSCEPTIBLE TO TREATMENT WITH A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | MERCK FROSST CANADA & CO. (CA) | 2002-10-15 | — | — | US | claimed |
| US-20020058690-A1 | For therapy and prophylaxis of inflammatory disease susceptible to treatment with a non- steroidal anti-inflammatory agent | MERCK FROSST CANADA LTD. (CA) | 2002-05-16 | — | — | US | claimed |
| WO-2002002547-A1 | PYRONES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA & CO. (CA) | 2002-01-10 | — | — | WO | claimed |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-12-07 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2020-02-20 | — | — | US | disclosed |
| EP-3509604-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | Trustees of Tufts College (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2019-07-11 | — | — | US | disclosed |
| US-20040204472-A1 | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents | PHARMACIA CORPORATION | 2004-10-14 | — | — | US | disclosed |
| WO-2004078113-A2 | TREATMENT AND PREVENTION OF OBESITY WITH COX-2 INHIBITORS ALONE OR IN COMBINATION WITH WEIGHT-LOSS AGENTS | PHARMACIA CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040147581-A1 | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy | PHARMACIA CORPORATION (US) | 2004-07-29 | — | — | US | disclosed |
| WO-2004045509-A2 | METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY | PHARMACIA CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-1299372-A1 | PYRONES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 2003-04-09 | — | — | EP | disclosed |
| US-6465509-B2 | FOR THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISEASE SUSCEPTIBLE TO TREATMENT WITH A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | MERCK FROSST CANADA & CO. (CA) | 2002-10-15 | — | — | US | disclosed |
| US-20020058690-A1 | For therapy and prophylaxis of inflammatory disease susceptible to treatment with a non- steroidal anti-inflammatory agent | MERCK FROSST CANADA LTD. (CA) | 2002-05-16 | — | — | US | disclosed |
| WO-2002002547-A1 | PYRONES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA & CO. (CA) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | PTGS2 2358/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | PTGS2 2466/4885 |
| US-20040147581-A1 | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy | HTR2A, HTR1A, TPH2 | PTGS2 19/4885 |
| US-20040204472-A1 | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | PTGS2 24/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | PTGS2 24/4885 |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885 |
| US-20020058690-A1 | For therapy and prophylaxis of inflammatory disease susceptible to treatment with a non- steroidal anti-inflammatory agent | PTGS1, PTGES2, PTGS2 | PTGS2 3/4885 |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | PTGS2 24/4885 |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | PTGS2 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.